GNRH1 and endometrial cancer: GnRH antagonists caused anti-proliferative effects in most endometrial cancer, breast cancer, and ovarian cancer cell lines, suggesting that the dichotomy of GnRH agonists and antagonists might not apply to the GnRH system in many tumors (6, 13).